Contineum Therapeutics (CTNM), which is developing therapies for multiple sclerosis and idiopathic pulmonary fibrosis, has filed for a proposed $150M initial public offering. The biotech company didn’t specify any terms in its SEC filing, but indicated its filing fee schedule that it was looking to raise around $150M. Contineum hopes to list its shares on Nasdaq under the symbol CTNM. Bookrunners include Goldman Sachs, Morgan Stanley, Stifel and RBC Capital Markets. Based in San Diego, the company has two drugs in early-to-mid stage clinical development.